Lavanya Yohanathan

1.6K posts

Lavanya Yohanathan

Lavanya Yohanathan

@LYohanathan

Hepatopancreatobiliary surgeon @ MHP, interest in transplant oncology. Mayo Clinic Alum. Opinions my own

Royal Oak, MI Beigetreten Temmuz 2017
991 Folgt1.3K Follower
Lavanya Yohanathan
Lavanya Yohanathan@LYohanathan·
Neoadjuvant intent treatment for high risk hcc should be considered in patients. The data is there… let’s encourage this strategy!
Beau Bosko Toskich, MD FSIR@BeauToskichMD

⬇️DOWNSTAGING patients with #HCC and Macrovascular Invasion to curative intent should be a FIRST-LINE strategy. It involves both local and systemic therapy. No room for turf nonsense. 🤝 📣"VP1-3 and normalize AFP" Fight for your patients' BIG WIN. ⚔️ 🧩 #Y90 #immunotherapy #SBRT #Transplant #Livertwitter @OncBrothers @brunolarvol @ASTSChimera @AASLDtweets @UHNTransplant jhep-reports.eu/article/S2589-…

English
0
0
5
1.3K
Iswanto Sucandy MD
Iswanto Sucandy MD@IswantoSucandy·
Excellent academic and clinical discussion on: 1. Management of Hemorrhagic Hepatic Cyst 2. Treatment/Preparation of Echinococcal Cyst Resection Congratulations for our fellows representing our Tampa HPB program, Dr Edward Cho for moderating and Dr Jayerajah for leading!
Iswanto Sucandy MD tweet mediaIswanto Sucandy MD tweet media
English
2
4
19
1.9K
Lavanya Yohanathan retweetet
Thor Halfdanarson
Thor Halfdanarson@OncoThor·
Somatostatin analogs for high G2 (Ki-67 10-20%) and G3 NETs, worth trying or not? According to this retrospective study, the PFS in patients w/ high G2 NETs was 19 months vs. 6 months in G3. Patients with a higher liver tumor burden defined as >10% of liver volume had a shorter PFS but the number of patients was low. Take home message: SSAs are reasonable as initial therapy in high G2 and G3 NETs assuming follow up is close and patients are offered more effective therapy such as PRRT upon progression. onlinelibrary.wiley.com/doi/10.1111/jn…
English
2
8
38
2.5K
Lavanya Yohanathan retweetet
Thor Halfdanarson
Thor Halfdanarson@OncoThor·
To operate or not on panc NETs <2 cm…? The answer is NOT. Excellent presentation by @spartelli on the long term outcomes of the ASPEN trial. Almost 1000 patients observed w/o resection and progression was uncommon, mets rare and survival the same as with resection.
Thor Halfdanarson tweet mediaThor Halfdanarson tweet mediaThor Halfdanarson tweet mediaThor Halfdanarson tweet media
English
3
47
117
8.7K
Lavanya Yohanathan retweetet
Patricio Polanco
Patricio Polanco@PatricioPolanc0·
Please join us for this Society of Surgical Oncology discussion about the Intersection of Hepatobiliary and Peritoneal Surface Malignancies with experts panelists: David Bartlett, @DavidCabaMD , @ColinCourtMD Deepa Magge, @SyedKazmiMD @KLafaro Jula Verapoong @SinzianaDumitra
Society of Surgical Oncology@SocSurgOnc

Join us for a discussion on the management of patients with dual metastases to the liver and peritoneum. A panel of experts will walk through the decision-making process in these cases, offering clinical perspectives. Don’t miss this webinar: learn.surgonc.org/courses/115195…

English
0
5
19
2.3K
Lavanya Yohanathan
Lavanya Yohanathan@LYohanathan·
Excellent work and long awaited results of ASPEN trial by @spartelli !!! It is safe to observe pancreatic net <2cm!!
Julie Hallet@HalletJulie

📢 Small NF PanNETs can/should be observed #ASPEN🏔️ @spartelli #ESMO25 👥Prospective multi-centre cohort 1️⃣0️⃣0️⃣0️⃣ PanNETs <2cm An image 🏞️ is worth 1000 words👇🏻 For resection: 😳NNT 276 ⚠️NNH 6 ✅No difference in OS surgery vs active surveillance 👏Congrats on landmark work!

English
0
0
1
345
Stefano Partelli
Stefano Partelli@spartelli·
Excited to present at #ESMO2025 the results of the ASPEN study on 1,000 patients with pancreatic NETs <2 cm. What do you think the data will support? Surgery 🔪 or observation 🔭 @myESMO
English
3
9
19
4.7K
Judy Boughey
Judy Boughey@DrJudyBoughey·
Great catching up with prior trainees from @MayoClinicSurg - now successful breast, endocrine and HPB surgeons around the country. What a fun evening in Chicago.
Judy Boughey tweet mediaJudy Boughey tweet media
English
2
1
21
4.7K
Lavanya Yohanathan retweetet
Julie Hallet
Julie Hallet@HalletJulie·
🌀Do CRLM truly disappear after chemo? DREAM study:👥233 pts MRI + CT most accurate ❌63% truly nonviable 👀24% visible on intraop US No change OS with resection vs not (small numbers) 🤔If disappeared CRLM: plan resection or trust it disappeared? t.co/gPVsGU9pFP
Julie Hallet tweet mediaJulie Hallet tweet mediaJulie Hallet tweet media
English
3
28
74
10.3K
Julie Hallet
Julie Hallet@HalletJulie·
Bringing surg onc & HPB together at #CSF2025 Resecting liver mets for gastric, sarcoma or breast cancer - benefit or “cosmetic surgery for the radiologist”? To consider in highly selected patients - some robust discussions with experts including visiting speaker @alegronchi
Julie Hallet tweet media
English
2
9
37
2.2K
Lavanya Yohanathan retweetet
Michael Lidsky, MD, FACS
Michael Lidsky, MD, FACS@michael_lidsky·
Shout it from the rooftops! Determination of technical resectability is best left to the liver surgeon, and all patients deserve to be evaluated by one. But the decision to operate, and when, remains a multidisciplinary decision.
Lee M. Ocuin MD, FACS@TheNotoriousHPB

Nicely written editorial by @VictoriaSWu_ providing our perspective on CAIRO5, the importance of evaluation by an HPB surgeon & metastesectomy, and the lack of a standardized definition of resectability. @LVHN @TJUHospital @BrighamSurgery @michael_lidsky jgo.amegroups.org/article/view/1…

English
2
6
20
4.9K

Entdecken

@AHPBA @NabeelZafarMD @SyedAAhmad5 @SocSurgOnc @IswantoSucandy @AdventHealth @SSATNews @SAGES_Updates